AR112901A1 - Preparación de formas de dosificación sólidas que comprenden anticuerpos por estratificación de solución / suspensión - Google Patents
Preparación de formas de dosificación sólidas que comprenden anticuerpos por estratificación de solución / suspensiónInfo
- Publication number
- AR112901A1 AR112901A1 ARP180102681A ARP180102681A AR112901A1 AR 112901 A1 AR112901 A1 AR 112901A1 AR P180102681 A ARP180102681 A AR P180102681A AR P180102681 A ARP180102681 A AR P180102681A AR 112901 A1 AR112901 A1 AR 112901A1
- Authority
- AR
- Argentina
- Prior art keywords
- dosage forms
- solid dosage
- solution
- preparation
- forms including
- Prior art date
Links
- 239000007909 solid dosage form Substances 0.000 title abstract 4
- 239000000725 suspension Substances 0.000 title abstract 2
- 238000013517 stratification Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 238000003475 lamination Methods 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Método para preparar formas de dosificación sólidas de liberación inmediata y sostenida, que comprende anticuerpos y fragmentos funcionales de los mismos, mediante estratificación en solución / suspensión, opcionalmente revestido con un recubrimiento de liberación retardada; las formas de dosificación sólidas preparadas por el método; y el uso de las formas de dosificación sólidas en el tratamiento tópico en el tracto gastrointestinal de un paciente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17192260.2A EP3459528B1 (en) | 2017-09-20 | 2017-09-20 | Preparation of solid dosage forms comprising antibodies by solution/suspension layering |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112901A1 true AR112901A1 (es) | 2019-12-26 |
Family
ID=59923358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180102681A AR112901A1 (es) | 2017-09-20 | 2018-09-20 | Preparación de formas de dosificación sólidas que comprenden anticuerpos por estratificación de solución / suspensión |
Country Status (24)
Country | Link |
---|---|
US (2) | US11826470B2 (es) |
EP (2) | EP3459528B1 (es) |
JP (2) | JP7204743B2 (es) |
KR (1) | KR20200055711A (es) |
CN (1) | CN111093635A (es) |
AR (1) | AR112901A1 (es) |
AU (2) | AU2018337493B2 (es) |
BR (1) | BR112020005460A8 (es) |
CA (1) | CA3075862A1 (es) |
CL (1) | CL2020000735A1 (es) |
CO (1) | CO2020003070A2 (es) |
CR (2) | CR20210203A (es) |
EA (1) | EA202090640A8 (es) |
ES (1) | ES2938609T3 (es) |
GE (2) | GEP20237504B (es) |
IL (1) | IL272933A (es) |
JO (1) | JOP20200064A1 (es) |
MA (1) | MA50157A (es) |
MX (1) | MX2020003032A (es) |
PH (1) | PH12020500353A1 (es) |
SA (1) | SA520411573B1 (es) |
SG (1) | SG11202002203YA (es) |
TW (1) | TWI802592B (es) |
WO (1) | WO2019057562A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3459528B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Preparation of solid dosage forms comprising antibodies by solution/suspension layering |
CN112263564B (zh) * | 2020-10-30 | 2022-07-19 | 黄山中皇制药有限公司 | 一种喜炎平干混悬剂的制备方法 |
CN112107694B (zh) * | 2020-10-30 | 2022-07-22 | 黄山中皇制药有限公司 | 一种喜炎平干混悬剂 |
CN116236463A (zh) * | 2023-02-16 | 2023-06-09 | 山东省药学科学院 | 右酮洛芬缓释微丸胶囊及其制备方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
IT1246382B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
AU664561B2 (en) | 1991-06-21 | 1995-11-23 | University Of Cincinnati, The | Orally administrable therapeutic proteins and method of making |
EP0725789B1 (en) | 1993-09-20 | 2003-03-19 | Anadis Ltd. | Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition |
NO309690B1 (no) | 1995-01-23 | 2001-03-12 | Western Atlas Int Inc | Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn |
WO2000018500A1 (de) | 1998-09-24 | 2000-04-06 | Glatt Systemtechnik Dresden Gmbh | Einrichtung zur herstellung eines schüttfähigen produktes und verfahren zur anwendung der einrichtung |
PL342710A1 (en) | 1997-12-20 | 2001-07-02 | Genencor Int | Matrix granule |
US6074689A (en) * | 1998-03-10 | 2000-06-13 | Immucell Corporation | Colonic delivery of protein or peptide compositions |
FI20000780A (fi) | 2000-04-03 | 2001-10-04 | Novasso Oy | Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi |
GB2367002A (en) | 2000-09-25 | 2002-03-27 | British Sugar Plc | Coating composition |
GB0203421D0 (en) | 2002-02-13 | 2002-04-03 | Alizyme Therapeutics Ltd | Composition |
US9107804B2 (en) | 2002-12-10 | 2015-08-18 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
EP1589951B1 (en) | 2003-01-03 | 2017-08-09 | Supernus Pharmaceuticals, Inc. | Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics |
DE10332160A1 (de) | 2003-07-15 | 2005-02-03 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
DE10353186A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
EP1755557A4 (en) | 2004-05-19 | 2007-08-29 | Glatt Air Tech Inc | GRANULES CONTAINING MICROGRANULES AND PROCESS FOR THE PREPARATION THEREOF |
JP2008534530A (ja) * | 2005-03-29 | 2008-08-28 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 活性成分放出に関して調節作用を有する物質を有するペレットを含有している多粒子薬剤形 |
BRPI0611765B1 (pt) | 2005-06-07 | 2022-09-27 | Esbatech Ag | Anticorpo ou fragmento de anticorpo estável e solúvel que se liga especificamente ao tnf-alfa seus usos e composição diagnóstica ou terapêutica |
EP2777695B1 (en) | 2006-02-09 | 2018-09-12 | Alba Therapeutics Corporation | Formulations for a tight junction effector |
GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
CA2684655A1 (en) | 2007-03-26 | 2008-10-02 | Teikoku Seiyaku Co., Ltd. | Oral pharmaceutical preparation for colon-specific delivery |
WO2009037264A2 (en) * | 2007-09-17 | 2009-03-26 | Da Volterra | Colonic delivery of antimicrobial agents |
CA2615137A1 (en) * | 2007-12-17 | 2009-06-17 | Pharmascience Inc. | Single layered controlled release therapeutic system |
AU2009203123A1 (en) | 2008-01-03 | 2009-07-09 | Abbott Products Gmbh | Pharmaceutical compositions comprising granules of purified microbial lipase and methods of preventing or treating digestive disorders |
JP5856480B2 (ja) | 2008-06-25 | 2016-02-09 | エスバテック − ア ノバルティスカンパニー エルエルシー | 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化 |
ES2861592T3 (es) | 2008-06-25 | 2021-10-06 | Novartis Ag | Anticuerpos estables y solubles que inhiben el TNF |
BRPI0915460A2 (pt) | 2008-07-10 | 2015-11-10 | Esbatech Alcon Biomed Res Unit | métodos e composições para a liberação intensificada de macromoléculas |
EP2340812A1 (en) | 2009-12-18 | 2011-07-06 | Ferring International Center S.A. | Granules for pharmaceutical preparations, methods and apparatus for their production |
EP2691415B1 (en) * | 2011-03-28 | 2018-07-11 | Ablynx N.V. | Method for producing solid formulations comprising immunoglobulin single variable domains |
WO2014142938A1 (en) | 2013-03-15 | 2014-09-18 | Aihol Corporation | Pharmaceutical formulation containing glycosaminoglycan |
FR3022462B1 (fr) * | 2014-06-18 | 2018-04-27 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Composition orale d'anticorps anti-tnfalpha |
EP3459528B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Preparation of solid dosage forms comprising antibodies by solution/suspension layering |
-
2017
- 2017-09-20 EP EP17192260.2A patent/EP3459528B1/en active Active
- 2017-09-20 ES ES17192260T patent/ES2938609T3/es active Active
-
2018
- 2018-09-11 JO JOP/2020/0064A patent/JOP20200064A1/ar unknown
- 2018-09-11 MX MX2020003032A patent/MX2020003032A/es unknown
- 2018-09-11 EP EP18765136.9A patent/EP3684339A1/en active Pending
- 2018-09-11 CR CR20210203A patent/CR20210203A/es unknown
- 2018-09-11 GE GEAP201815611A patent/GEP20237504B/en unknown
- 2018-09-11 MA MA050157A patent/MA50157A/fr unknown
- 2018-09-11 BR BR112020005460A patent/BR112020005460A8/pt unknown
- 2018-09-11 KR KR1020207006918A patent/KR20200055711A/ko not_active IP Right Cessation
- 2018-09-11 CR CR20200130A patent/CR20200130A/es unknown
- 2018-09-11 GE GEAP201815318A patent/GEP20227351B/en unknown
- 2018-09-11 JP JP2020515749A patent/JP7204743B2/ja active Active
- 2018-09-11 AU AU2018337493A patent/AU2018337493B2/en active Active
- 2018-09-11 SG SG11202002203YA patent/SG11202002203YA/en unknown
- 2018-09-11 US US16/647,322 patent/US11826470B2/en active Active
- 2018-09-11 EA EA202090640A patent/EA202090640A8/ru unknown
- 2018-09-11 CA CA3075862A patent/CA3075862A1/en active Pending
- 2018-09-11 CN CN201880059373.2A patent/CN111093635A/zh active Pending
- 2018-09-11 WO PCT/EP2018/074520 patent/WO2019057562A1/en active Application Filing
- 2018-09-17 TW TW107132680A patent/TWI802592B/zh active
- 2018-09-20 AR ARP180102681A patent/AR112901A1/es unknown
-
2020
- 2020-02-18 PH PH12020500353A patent/PH12020500353A1/en unknown
- 2020-02-26 IL IL272933A patent/IL272933A/en unknown
- 2020-03-16 CO CONC2020/0003070A patent/CO2020003070A2/es unknown
- 2020-03-19 SA SA520411573A patent/SA520411573B1/ar unknown
- 2020-03-20 CL CL2020000735A patent/CL2020000735A1/es unknown
-
2022
- 2022-12-28 JP JP2022211549A patent/JP2023036901A/ja active Pending
-
2023
- 2023-11-27 US US18/520,348 patent/US20240099980A1/en active Pending
-
2024
- 2024-09-03 AU AU2024219328A patent/AU2024219328A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020003070A2 (es) | Preparación de formas de dosificación sólida que comprenden anticuerpos por estratificación de solución/suspensión | |
CL2019000334A1 (es) | Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357) | |
SV2018005610A (es) | Derivados de oxopiridina sustituidos | |
CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
CL2017001217A1 (es) | Conjugados de droga de anticuerpos. | |
WO2015069794A3 (en) | Novel anti-claudin antibodies and methods of use | |
WO2015089449A3 (en) | Novel anti-dpep3 antibodies and methods of use | |
MX2015009105A (es) | Composiciones en solucion solida y su uso en inflamacion cronica. | |
CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
CL2015000784A1 (es) | Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades. | |
CL2016003214A1 (es) | Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
CO2019011227A2 (es) | N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso | |
EP3306361A4 (en) | REFLECTIVE LIGHT-EMITTING FILM, MANUFACTURING METHOD AND USE THEREOF | |
CL2016001510A1 (es) | Células madre derivadas de musculo de mamifero | |
EP3395834A4 (en) | ANTI-TPBG ANTIBODIES AND ITS PREPARATION METHOD, CONJUGATED AND USE THEREOF | |
NI201900023A (es) | 1 - arilnaftiridin-3-carboxamidas 7-sustituidas y su uso | |
ES2609817T3 (es) | Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida | |
AR112701A1 (es) | Método para preparar una forma de dosificación sólida que comprende anticuerpos por granulación en húmedo, extrusión y esferonización |